NP G2 044

Drug Profile

NP G2 044

Alternative Names: NP-G2-044

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novita Pharmaceuticals; Weill Cornell Medical College
  • Class Antineoplastics
  • Mechanism of Action Cell movement inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 20 Jul 2017 Chemical structure information added
  • 30 Jun 2017 Novita Pharmaceuticals plans a phase I trial for Solid tumours (Metastatic disease) in USA (NCT03199586)
  • 01 Apr 2016 Preclinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top